Monitoring treatment of colorectal cancer patients with drugs targeting EGFR pathway using mass spectrometry of patient samples
| Title: | Monitoring treatment of colorectal cancer patients with drugs targeting EGFR pathway using mass spectrometry of patient samples |
|---|---|
| Patent Number: | 8,586,379 |
| Publication Date: | November 19, 2013 |
| Appl. No: | 13/313791 |
| Application Filed: | December 07, 2011 |
| Abstract: | Methods using mass spectral data analysis and a classification algorithm provide an ability to determine whether a non-small-cell lung cancer patient, head and neck squamous cell carcinoma or colorectal cancer patient has likely developed a non-responsiveness to treatment with a drug targeting an epidermal growth factor receptor pathway. As the methods of this disclosure require only simple blood samples, the methods enable a fast and non-intrusive way of measuring when drugs targeting the EGFR pathway cease to be effective in certain patients. This discovery represents the first known example of true personalized selection of these types of cancer patients for treatment using these classes of drugs not only initially, but during the course of treatment. |
| Inventors: | Röder, Heinrich (Steamboat Springs, CO, US); Tsypin, Maxim (Steamboat Springs, CO, US); Grigorieva, Julia (Steamboat Springs, CO, US) |
| Assignees: | Biodesix, Inc. (Boulder, CO, US) |
| Claim: | 1. A method of facilitating treatment of a colorectal cancer (CRC) patient comprising the steps of: 1) assigning a baseline class label for the patient using a classifier operating on integrated intensity values at pre-defined m/z ranges in mass-spectral data obtained from a blood-based sample of the patient and a training set comprising class-labeled spectra from other patients, the baseline class label indicating whether the patient is likely to benefit from administration of a drug targeting an epidermal growth factor receptor pathway by inhibiting tyrosine kinase or interfering with EGFR, wherein if the baseline class label indicates the patient is likely to benefit, the drug is administered to the patient; and 2) thereafter, while the patient is being treated with the drug, a) obtaining a mass spectrum of a blood-based sample of the patient, b) performing one or more predefined pre-processing steps on the mass spectrum, c) obtaining integrated intensity values of selected features in said spectrum at one or more pre-defined m/z ranges after the pre-processing steps on the mass spectrum have been performed, and d) assigning a further class label for the sample using the classifier and the training set, the further class label indicating whether the patient has developed a non-responsiveness to the treatment with the said drug. |
| Claim: | 2. The method of claim 1 , wherein step 2) including sub-steps a)-d) are performed periodically during the course of treatment of the patient. |
| Claim: | 3. The method of claim 1 , wherein the one or more pre-defined m/z ranges comprises one or more m/z ranges selected from the group of m/z ranges consisting of: 5732 to 5795 5811 to 5875 6398 to 6469 11376 to 11515 11459 to 11599 11614 to 11756 11687 to 11831 11830 to 11976 12375 to 12529 23183 to 23525 23279 to 23622 and 65902 to 67502. |
| Claim: | 4. The method of claim 1 , wherein the steps a)-d) are performed at intervals of between 30 and 100 days. |
| Current U.S. Class: | 436/173 |
| Patent References Cited: | 7736905 June 2010 Roder et al. 7858389 December 2010 Roder et al. 7858390 December 2010 Roder et al. 7867775 January 2011 Roder et al. 7879620 February 2011 Roder et al. 7906342 March 2011 Roder et al. 2005/0048547 March 2005 Zhao et al. 2005/0164218 July 2005 Agus et al. 2005/0267689 December 2005 Tsypin 2006/0029574 February 2006 Albitar et al. 2007/0231921 October 2007 Roder et al. 2009/0170216 July 2009 Roder et al. 2009/0171872 July 2009 Roder et al. 2009/0204334 August 2009 Semmes et al. 2010/0055100 March 2010 Roder et al. 2010/0174492 July 2010 Roder et al. 2011/0121167 May 2011 Roder et al. 2011/0121169 May 2011 Roder et al. WO 2004/012588 February 2004 WO 2005/010492 February 2005 WO2005/094357 October 2005 WO 2005/098445 October 2005 WO2007/001868 January 2007 WO2007/109571 September 2007 WO2010/085234 July 2010 |
| Other References: | Fukuoka, M. et al. Biomarker analyses from a phase III, randomized, open-label, first-line study of gefitinib (G) versus carboplatin/paclitaxel (C/P) in clinically selected patients (pts) with advanced nonsmall cell lung cancer (NSCLC) in Asia (IPASS), 2009, Journal of Clinical Oncology, vol. 27(15s). cited by examiner Khambata-Ford, S. et al. Analysis of Potential Predictive Markers of Cetuximab Benefit in BMS099, a Phase III Study of Cetuximab and First-Line Taxane/Carboplatin in Advanced Non-Small-Cell Lung Cancer, 2010, JOurnal of Clinical Onconlogy, vol. 28(6), pp. 918-927. cited by examiner Brugger, W. et al. Biomarker analyses from the phase III placebo-controlled SATURN study of maintenance erlotinib following first-line chemotherapy for advanced NSCLC, 2009, Journal of Clinical Oncology, vol. 27(15s). cited by examiner Dahabreh, I.J., et al. Somatic EGFR Mutation and Gene Copy Gain as Predictive Biomarkers for Response to Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer, 2009, Clinical Cancer Research, vol. 16(1), pp. 291-303. cited by examiner Lievre, A. et al., KRAS mutation status is predictive of response to cetuximab therapy in calorectal cancer, 2006, Cancer Research, vol. 66(8), pp. 3992-3995. cited by examiner Calvo, K.R., et al. Clinical proteromics: from biomarker discovery and cell signaling profiles to individualized personal therapy, 2005, Bioscience Reports, vol. 25, pp. 107-125. cited by examiner Gottesman, M.M. et al. Genetic analysis of the multidrug transporter, 1995, Annu. Rev. Genet. vol. 29, pp. 607-649. cited by examiner Extended European Search Report in EP 07754043.3, dated Aug. 6, 2009. cited by applicant Bhanot et al., A Robust Meta-Classification Strategy for Cancer Detection from MS Data, Proteomics, vol. 6, pp. 592-604 (2006). cited by applicant Metro, et al., “Epidermal Growth Factor Receptor (EGFR) Targeted Therapies in Non-Small Cell Lung Cancer (NSCLC)”, Reviews on Recent Clinical Trials, vol. 1, No. 1, pp. 1-13 (2006). cited by applicant Taguchi, et al., “Mass Spectrometry to Classify Non-Small-Cell Lung Cancer Patients for Clinical Outcome after Treatment with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: A Multicohort Cross-Institutional Study”, Journal of the National Cancer Institute, vol. 99, Issue 11, pp. 838-846 (2007). cited by applicant Ladanyi, et al., “Lung adenocarcinoma: guiding EGFR-targeted therapy and beyond”, Modern Pathology, vol. 21, pp. S16-S22 (2008). cited by applicant Engelman et al. Mechanisms of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer, Clin. Cancer Res. 2008; 14(10) pp. 2895-2899 (May 15, 2008). cited by applicant Lynch et al., Activating Mutations in the Epiderman Growth Factor Receptor Underlying Responsiveness of Non-Small-Call lung Cancer to Getfitinib, The New England Journal of Medicine, vol. 350, No. 21, pp. 2129-2139 (2004). cited by applicant Extended European Search Report dated Aug. 25, 2010 in European Application No. 10003343.0. cited by applicant Reyzer et al. MALDI mass spectrometry for direct tissue analysis: a new tool for biomarker discovery, Journal of Proteome Research vol. 4, No. 4, pp. 1138-1142 (2005). cited by applicant Yanagisawa et al. Proteomic patterns of tumour subsets in non-small-cell lung cancer, The Lancet, vol. 362, pp. 433-439 (Aug. 9, 2003). cited by applicant Howard et al. Identification and validation of a potential lung cancer serum biomarker detected by matrix-assisted laser desorption/ionization-time of flight spectra analysis, Proteomics vol. 3, pp. 1720-1724 (2003). cited by applicant D. Coomans and D.L. Massart, Alternative k-Nearest Neighbour Rules in Supervised Pattern Recognition, Part 1, Analytica Chimica Acta, 136, pp. 15-27 (1982). cited by applicant Office Action in EP application No. 07754043.3 dated Sep. 14, 2010. cited by applicant Daemen Anneleen et al., Integrating microarray and proteomics data to predict the response on cetuximab in patients with rectal cancer, Pacific Symposium on Biocomputing, 2008, pp. 166-177, XP002566184 ISSN: 1793-5091. cited by applicant Spano et al., Potential predictive markers of response to EGFR-targeted therapies in colorectal cancer, Critical Reviews in Oncology/Hematology, Elsevier Science Ireland LTD., Limerick, IE, vol. 66, No. 1, Feb. 21, 2008, pp. 21-30, XP022512189, ISSN: 1040-8428. cited by applicant Smith, Fraser M. et al., Combination of SELDI-TOF-MS and data mining provides early-stage response prediction for rectal tumors undergoing multimodal neoadjuvant therapy, Annals of Surgery Feb. 2007, vol. 245, No. 2, Feb. 2007 pp. 259-266, XP002566185, ISSN: 0003-4932. cited by applicant Reymond M A et al., Expression and functional proteomics studies in colorectal cancer, Pathology Research and Practice, Gustav Fischer, Stuttgart, DE, vol. 200, No. 2, Apr. 30, 2004, pp. 119-127, XP004959031, ISSN: 0344-0338. cited by applicant Oda Kanae et al., A comprehensive pathway map of epidermal growth factor receptor signaling, Molecular Systems Biology 2005, vol. 1, 2005, XP002565681, ISSN: 1744-4292. cited by applicant Duncan M W et al., Quantitative matrix-assisted laser desorption/ionization mass spectrometry, Briefings in Functional Genomics and Proteomics-Special Issue: Topics in Quantitative Biological Mass Spectometry 2008 GB, vol. 7, No. 5, 2008, pp. 355-370, XP008117942. cited by applicant International Search Report and Written Opinion in PCT/US2007/007467 dated Nov. 8, 2007. cited by applicant Fleming et al., Windowed mass selection method: a new data processing algorithm for liquid chromatography-mass spectrometry data, Journal of Chromotography A, vol. 849, pp. 71-85 (1999). cited by applicant Senko et al., Determination of monoisotopic masses and ion population for large biomolecules from resolved isotopic distribution, Journal of the American Society for Mass Spectometry, vol. 6, pp. 229-22 (1995). cited by applicant Gras et al., Improving protein identification from peptide mass fingerprinting through a parameterized multi-level scoring algorithm and an optimized peak detection, Electrophoresis, vol. 20, pp. 3535-3550 (1999). cited by applicant Alfassi, On the normalization of a mass spectrum for comparison of two spectra, American Society for Mass Spectometry, vol. 15, pp. 385-387 (2004). cited by applicant Koenker et al., Quantile Smoothing Splines, Biometrika vol. 81, pp. 673-680 (1994). cited by applicant Eilers, Parametric Time Warping, Analytical Chemistry, vol. 76, No. 2, pp. 401-411 (2004). cited by applicant Search Report and Written Opinion Feb. 16, 2010 in PCT/US2009/006267,filed Nov. 20, 2009. cited by applicant Gourin et al., Serum Protein Profile Analysis Following Definitive Treatment in Patients with Head and Neck Squamous Cell Carcinoma, Archives of Otolaryngology—Head and Neck Surgery, vol. 133 No. 11 pp. 1125-1130 (2007). cited by applicant Dietz et al., Current aspects of targeted therapy in head and neck tumors, European Archives of Oto-Rhino-Laryngology, vol. 265, suppl. 1 pp. S3-S12 (2008). cited by applicant Erjala et al., Clinical Cancer Res. 12(13):4103-4111, Jul. 1, 2006. cited by applicant *Zhen Xia et al., Serum Proteomic Profiles Suggest Celecoxib-Modulated Targets and Response Predictors, Cancer Research, vol. 64, pp. 2904-2909. Apr. 15, 2004. cited by applicant Frederick et al., Epithelial to mesenchymal transition predicts gefitinib resistance in cell lines of head and neck squamous cell carcinoma and non-small cell lung carcinoma, Molecular Cancer Theraputics, 2007;6(6) pp. 1683-1691, Jun. 2007. cited by applicant Chung et al., Detection of Tumor.Epidermal Growth Factor Receptor Pathway Dependence by Serum Mass Spectrometry in Cancer Patients, Cancer Epidemiol Biomarkers Prev, vol. 19 (2), pp. OF1-OF8 and Suppl., Jan. 19, 2010. cited by applicant |
| Primary Examiner: | Xu, Robert |
| Attorney, Agent or Firm: | McDonnell Boehnen Hulbert & Berghoff LLP |
| Accession Number: | edspgr.08586379 |
| Database: | USPTO Patent Grants |
| Language: | English |
|---|